1226549-62-7

Basic information

• Product Name: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol
• Synonyms: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol
• CAS NO: 1226549-62-7
• Molecular Weight: 452.469
• Mol File: 1226549-62-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol(1226549-62-7)
• EPA Substance Registry System: (2S)-2-{[5-(3-nitrophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol(1226549-62-7)

Safety Data

• Hazardous Substances Data: 1226549-62-7(Hazardous Substances Data)

Upstream product

• 1073135-81-5 5-bromo-4-chloro-6-phenylfuro[2,3-d]pyrimidine 
• 65148-07-4 4-chloro-5,6-diphenylfuro[2,3-d]pyrimidine 
• 1226548-51-1 (2S)-2-[(5-bromo-6-phenylfuro[2,3-d]pyrimidin-4-yl)amino]-2-phenylethanol 
• 13331-27-6 m-nitrobenzene boronic acid 

Downstream Products

• 1226549-64-9 (2S)-2-{[5-(3-aminophenyl)-6-phenylfuro[2,3-d]pyrimidin-4-yl]amino}-2-phenylethanol 

Relevant articles and documents

Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol

Fast-forwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification

A focused library of furanopyrimidine (350 compounds) was rapidly synthesized in parallel reactors and in situ screened for Aurora and epidermal growth factor receptor (EGFR) kinase activity, leading to the identification of some interesting hits. On the basis of structural biology observations, the hit 1a was modified to better fit the back pocket, producing the potent Aurora inhibitor 3 with submicromolar antiproliferative activity in HCT-116 colon cancer cell line. On the basis of docking studies with EGFR hit 1s, introduction of acrylamide Michael acceptor group led to 8, which inhibited both the wild and mutant EGFR kinase and also showed antiproliferative activity in HCC827 lung cancer cell line. Furthermore, the X-ray cocrystal study of 3 and 8 in complex with Aurora and EGFR, respectively, confirmed their hypothesized binding modes. Library construction, in situ screening, and structure-based drug design (SBDD) strategy described here could be applied for the lead identification of other kinases.